Zydus Lifesciences Limited has completed the acquisition of biologics manufacturing assets from Agenus Inc. following the completion of all required regulatory approvals, including clearance from the Committee on Foreign Investment in the United States (CFIUS). The transaction covers an Asset Purchase Agreement, Share Purchase Agreement and an exclusive Licensing Agreement between the two companies..

Zydus Lifesciences Limited 已完成从 Agenus Inc. 收购生物制品制造资产，此前所有必要的监管审批均已结束，包括获得美国外国投资委员会 (CFIUS) 的批准。该交易涵盖两家公司之间的资产购买协议、股份购买协议以及独家许可协议。

With this acquisition, Zydus strengthens its presence in the global biologics contract development and manufacturing (CDMO) market. The acquired manufacturing assets and operations will be brought under a new US-based subsidiary, Zylidac Bio LLC.

通过此次收购，Zydus加强了其在全球生物制品合同开发和生产（CDMO）市场的地位。所收购的制造资产和运营将归入一家新的美国子公司Zylidac Bio LLC。

Zylidac Bio LLC will operate biologics manufacturing plants in the US and offer CDMO services to biopharmaceutical companies worldwide. The new subsidiary supports the growing focus on secure, domestic and high-quality supply chains for advanced biological therapies, while also enabling Zydus to expand its manufacturing and service capabilities for the international biopharmaceutical sector..

Zylidac Bio LLC 将在美国运营生物制品生产工厂，并为全球生物制药公司提供CDMO服务。这家新子公司支持对安全、国内和高质量供应链日益增长的关注，同时也使 Zydus 能够拓展其在国际生物制药领域的制造和服务能力。

The launch of Zylidac Bio LLC comes at a time when the BIOSECURE Act, signed into law on 18 December 2025, limits US government agencies from working with certain biotechnology companies. By investing in a compliant, US-based manufacturing footprint in California, Zydus provides an option for global biopharmaceutical companies looking to shift their supply chains to approved domestic partners..

Zylidac Bio LLC 的成立正值《生物安全法案》（BIOSECURE Act）生效之际，该法案于2025年12月18日签署成为法律，限制美国政府机构与特定生物技术公司合作。通过在加利福尼亚州投资建设合规的美国本土生产基地，Zydus 为寻求将供应链转移至经批准的国内合作伙伴的全球生物制药公司提供了一个选择。

Earlier in 2025, Zydus announced the expansion of its Global BioCDMO Services through the acquisition of Agenus’ advanced biologics manufacturing plants in Emeryville and Berkeley, California. Under an exclusive manufacturing arrangement, Zydus will be the sole supplier of drug substance and drug product for Agenus’ Phase III immuno-oncology candidates, botensilimab (BOT) and balstilimab (BAL).

2025年初，Zydus宣布通过收购Agenus位于加利福尼亚州埃默里维尔和伯克利的先进生物制品生产工厂，扩展其全球BioCDMO服务。根据独家制造协议，Zydus将成为Agenus三期免疫肿瘤候选药物botensilimab（BOT）和balstilimab（BAL）的药物原料和药物产品的唯一供应商。

Zydus has also secured exclusive rights to commercialise BOT and BAL in India and Sri Lanka..

Zydus还获得了在印度和斯里兰卡商业化BOT和BAL的独家权利。

Source: prnewswire.com

来源：prnewswire.com